These benefits, together with a earlier report showing that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like behavior in mice,2 support the notion of focusing on ACKR3 as a novel method to modulate the opioid program, which could open up new therapeutic avenues for opioid-associated disorders. In reaction to this https://mahatmaa047suv4.livebloggs.com/profile